New possibility to prevent and treat Parkinson's disease with licorice extract

November 9, 2017, DGIST (Daegu Gyeongbuk Institute of Science and Technology)
Senior researcher Yun-Il Lee of DGIST Well Aging Research Center. Credit: Daegu Gyeongbuk Institute of Science and Technology (DGIST)

DGIST's research team, led by Dr. Yun-Il Lee in Well Aging Research Center, has identified a new mechanism to inhibit dopaminergic neuronal apoptosis, a possible approach for preventing and treating Parkinson's disease (PD).

PD is a typical caused by the death of dopaminergic neurons in the middle cerebral blood. It is a with a higher incidence in people aged 60 or older, presenting symptoms such as tremor, stiffness, slow motion and postural instability.

In particular, as the majority of Parkinson's patients suffer from the , many researchers are focusing on the loss of dopamine-producing neurons. With regard to the cell death process, in vivo cell stress and damages activate PARP-1 (Poly ADP-ribose polymerase-1) and induce excessive accumulation of PAR (Poly ADP-ribose) and those activities activate apoptosis-inducing factor (AIF), which induces cell death and destroys DNA. This new mechanism of cell death (Parthanatos) has recently been identified as the cause of degenerative brain diseases such as Parkinson's disease, stroke, heart attack and diabetes, and the mechanism has been extensively studied in previous research to treat these diseases.

Currently, medications are being used to alleviate symptoms of Parkinson's disease. However, there are no government-approved drugs that can inhibit dopaminergic neuronal cell death. The research teams have now found a candidate in licorice.

Dr. Yun-Il Lee carried out joint research with Professor Joo-Ho Shin and Professor Yunjong Lee from Sungkyunkwan University School of Medicine to study candidate compounds for the treatment of Parkinson's disease. The researchers have identified the mechanism by which cortisol, a stress hormone, promotes dopaminergic neuronal activity by inducing parkin protein expression that inhibits dopamine neuronal cell death.

Mechanism of inhibition of dopamine neuronal cell death by Liquiritigenin : When mitochondrial function is impaired by active oxygen, MPP +, rotenone, 6-OHDA, and α-synuclein fibril, the activation of PARP1 causes DNA damage. In addition, the accumulation of the substrate AIMP2 of the parkin protein induces hyperactivity of PARP1 and results in cell death of dopaminergic neurons. Liquiritigenin inhibits dopamine neuronal cell death in Parkinson's disease as it binds to the estrogen receptor beta and is transported to the nucleus, stimulates transcription of RNF146 and controls the activation of PARP1. Credit: Daegu Gyeongbuk Institute of Science and Technology (DGIST)

In this study, the research teams found candidate drugs that induce the expression of RNF146 protein involved in the inhibition of neuronal cell death through a high-speed mass screening method using the natural materials library of the Natural Medicine Bank of Korea Foundation. As a result, the study has confirmed that liquiritigenin, a licorice extract, induces the expression of RNF146 protein and removes excessively accumulated PAR binding and modified substrate proteins using the ubiquitin proteasome system and results in inhibition of dopamine .

In addition, the research teams have been working on identifying the mechanism that induces liquiritigenin's RNF146 protein expression and demonstrated that it regulates transcription through binding and activity with estrogen receptors in cell and animal models. Consequently, it has been scientifically proved that liquiritigenin, a licorice extract, can be used as a treatment for degenerative Parkinson's disease.

Dr. Yun-Il Lee stated "Neuronal is involved in a variety of signaling systems in vivo. Therefore, it is essential to identify a new mechanism that is able to control the system comprehensively and we have found additional possibilities in licorice extract." He added, "I would like to contribute to the treatment of degenerative brain diseases such as Parkinson's disease by conducting advanced researches, comprehensive research and clinical studies."

This study has been published in the online edition of Oncotarget, international journal of oncology, on October 11.

Explore further: Team identifies mechanism of dopaminergic neuronal death inhibition using stress hormone cortisol

More information: Hyojung Kim et al, Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models, Oncotarget (2017). DOI: 10.18632/oncotarget.21828

Related Stories

Team identifies mechanism of dopaminergic neuronal death inhibition using stress hormone cortisol

April 26, 2017
DGIST's research team has found a candidate substance that can prevent and cure Parkinson's disease. By using this substance, the team also has identified the mechanism of dopaminergic neuronal death inhibition.

Dendritic Golgi as key cause of degenerative brain disease

August 11, 2017
A joint research team of DGIST (Daegu Gyeongbuk Institute of Science and Technology) has identified the early neuropathic mechanism of polyglutamine brain disease, one of the representative degenerative brain diseases. They ...

Discovery may offer hope to Parkinson's disease patients

May 22, 2017
The finding of a common protein abnormality in these degenerative diseases supports a hypothesis among experts that abnormal deposition of proteins in many neurodegenerative disorders reflects an early change in these proteins.

Conversion of brain cells offers hope for Parkinson's patients

April 11, 2017
Researchers at Karolinska Institutet have made significant progress in the search for new treatments for Parkinson's disease. By manipulating the gene expression of non-neuronal cells in the brain, they were able to produce ...

Treating with antioxidants early in Parkinson's disease process may halt degeneration and improve neuronal function

September 7, 2017
Northwestern Medicine scientists have identified a toxic cascade that leads to neuronal degeneration in patients with Parkinson's disease (PD) and figured out how to interrupt it, reports a study to be published September ...

An important study for Parkinson's disease: Researchers uncover mechanism regulating dopamine levels in the brain

December 11, 2014
Researchers in Montréal led by Jacques Drouin, D.Sc., uncovered a mechanism regulating dopamine levels in the brain by working on a mouse model of late onset Parkinson's disease. The study, conducted in collaboration with ...

Recommended for you

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

New brainstem changes identified in Parkinson's disease

January 4, 2018
A pioneering study has found that patients with Parkinson's disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area.

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Researchers shed light on why exercise slows progression of Parkinson's disease

December 22, 2017
While vigorous exercise on a treadmill has been shown to slow the progression of Parkinson's disease in patients, the molecular reasons behind it have remained a mystery.

Robotic device improves balance and gait in Parkinson's disease patients

December 19, 2017
Some 50,000 people in the U.S. are diagnosed with Parkinson's disease (PD) every year. The American Institute of Neurology estimates there are one million people affected with this neurodegenerative disorder, with 60 years ...

New findings point to potential therapy for Parkinson's Disease

December 19, 2017
A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson's disease and suggests that Tacrolimus—an existing drug that targets the toxic protein interaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.